PolyPid Secures $4.3M FDA Fee Waiver for D-PLEX₁₀₀ NDA, Accelerating Commercialization Focus
PYPD sits 99% above its 52-week low of $2.3.
Summary
PolyPid Ltd. announced it has received a $4.3 million PDUFA fee waiver from the FDA for its D-PLEX₁₀₀ New Drug Application (NDA). This significant financial benefit, representing approximately 5% of the company's market capitalization, allows PolyPid to reallocate resources towards critical commercialization preparations for its lead product candidate. The waiver comes as the company remains on track to initiate the rolling NDA submission for D-PLEX₁₀₀ by the end of this month, following successful Phase 3 SHIELD II trial results and positive pre-NDA feedback. This development is a strong positive signal for the regulatory pathway and financial health of the company as it moves closer to potentially bringing D-PLEX₁₀₀ to market. Investors will now watch for the formal NDA submission and updates on commercial partnership discussions.
At the time of this announcement, PYPD was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84M. The 52-week trading range was $2.30 to $5.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.